Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CΥP2C9 genotype

被引:146
作者
Yasar, Ü
Forslund-Bergengren, C
Tybring, G
Dorado, P
Llerena, A
Sjöqvist, F
Eliasson, E
Dahl, ML
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Dept Med Lab Sci & Technol, Div Clin Pharmacol, Stockholm, Sweden
[2] Univ Extremadura, Sch Med, Dept Pharmacol & Psychiat, Badajoz, Spain
关键词
D O I
10.1067/mcp.2002.121216
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and aim: Losartan is metabolized by polymorphic CYP2C9 to E-3174. Our aim was to evaluate the pharmacokinetics of losartan and E-3174 in relation to the CYP2C9 genotype. Methods: A 50-mg oral dose of losartan was given to 22 Swedish volunteers with different CYP2C9 genotypes. Losartan and E-3174 were analyzed by HPLC in plasma and urine samples collected up to 24 hours after drug intake. Furthermore, losartan and E-3174 were analyzed in 8-hour urine samples collected from 17 Spanish subjects after a single oral dose of 25 mg losartan. Results: The maximum plasma concentration of E-3174 was significantly (P < .05) lower in the CYP2C9*1/*3 (n = 5) and CYP2C9*2/*3 (n = 4) groups compared with the CYP2C9*1/*1 (n = 6) and CYP2C9*1/*2 (n = 3) groups and extremely low in 1 subject with the CYP2C9*3/*3 genotype. The ratio of the total losartan area under the plasma concentration-time curve (AUC) to the total E-3174 AUC (AUC(losartan)/AUC(E-3174)) was higher in the subject with the CYP2C9*3/*3 genotype (30-fold) and also in the CYP2C9*1/*3 and *2/*3 groups (approximately 2- and 3-fold, respectively) compared with the CYP2C9*1/*1 group. The plasma ratios correlated significantly with the 0- to 8-hour urinary losartan/E-3174 ratios. Among the total of 39 subjects, the urinary ratio was significantly higher in subjects with the CYP2C9*1/*3 (n = 10) and *2/*3 (n = 4) genotypes than in those with the CYP2C9*1/*1 genotype (n = 11; P < .01) and approximately 40-fold higher in subjects with the CYP2C9*3/*3 genotype (n = 3). Conclusion: The CYP2C9*3 allele was shown to be associated with decreased formation of E-3174 from losartan. The significant differences between genotypes in plasma and urine losartan/E-3174 ratios and the good correlation between the plasma and urine ratios suggest that the losartan/E-3174 ratio in 0- to 8-hour urine specimens may serve as a phenotyping assay for CYP2C9 activity. Further studies in larger populations will be required to establish this.
引用
收藏
页码:89 / 98
页数:10
相关论文
共 39 条
[21]   Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy [J].
Odani, A ;
Hashimoto, Y ;
Otsuki, Y ;
Uwai, Y ;
Hattori, H ;
Furusho, K ;
Inui, K .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (03) :287-292
[22]   A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin [J].
Rettie, AE ;
Haining, RL ;
Bajpai, M ;
Levy, RH .
EPILEPSY RESEARCH, 1999, 35 (03) :253-255
[23]   IMPAIRED (S)-WARFARIN METABOLISM CATALYZED BY THE R144C ALLELIC VARIANT OF CYP2C9 [J].
RETTIE, AE ;
WIENKERS, LC ;
GONZALEZ, FJ ;
TRAGER, WF ;
KORZEKWA, KR .
PHARMACOGENETICS, 1994, 4 (01) :39-42
[24]   An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection [J].
Ritter, MA ;
Furtek, CI ;
Lo, MW .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1997, 15 (07) :1021-1029
[25]   CLONING AND EXPRESSION OF COMPLEMENTARY DNAS FOR MULTIPLE MEMBERS OF THE HUMAN CYTOCHROME-P450IIC SUBFAMILY [J].
ROMKES, M ;
FALETTO, MB ;
BLAISDELL, JA ;
RAUCY, JL ;
GOLDSTEIN, JA .
BIOCHEMISTRY, 1991, 30 (13) :3247-3255
[26]   Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P4502C19) [J].
Sandwall, P ;
Lo, MW ;
Jonzon, B ;
Dalén, P ;
Furtek, C ;
Ritter, M ;
Alván, G ;
McCrea, J ;
Sjoqvist, F .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (04) :279-283
[27]   Genetic polymorphism of cytochrome P4502C9 in a Caucasian and a black African population [J].
Scordo, MG ;
Aklillu, E ;
Yasar, U ;
Dahl, ML ;
Spina, E ;
Ingelman-Sundberg, M .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (04) :447-450
[28]  
STEARNS RA, 1992, DRUG METAB DISPOS, V20, P281
[29]  
STEARNS RA, 1995, DRUG METAB DISPOS, V23, P207
[30]   The role of the CYP2C9-Leu(359) allelic variant in the tolbutamide polymorphism [J].
SullivanKlose, TH ;
Ghanayem, BI ;
Bell, DA ;
Zhang, ZY ;
Kaminsky, LS ;
Shenfield, GM ;
Miners, JO ;
Birkett, DJ ;
Goldstein, JA .
PHARMACOGENETICS, 1996, 6 (04) :341-349